The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of Nexplanon 68 mg implants. The contract has a ceiling value of $8,576.28 and a period of performance through December 2, 2024.
DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued up to $499,999,999 and valid through November 2026. This IDC enables the DLA to issue delivery orders for a broad range of pharmaceutical products and medical supplies to support the medical needs of military healthcare facilities worldwide. The current delivery order for Nexplanon implants is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure this direct federal award.
Generated 2/6/25, 9:27 AM